therapeutics

GDF10 exacerbates metastatic burden and cachexia in murine models of cancer.

Metastasis and cancer-induced cachexia significantly reduce survivorship and quality of life for cancer patients. GDF10 (BMP3b) is a TGF-ß superfamily ligand with little knowledge of its role in cancer progression. Some studies have shown that GDF10 exerts tumor-suppressive effects in...

🗓️ 2026-05-11
Read MoreGDF10 exacerbates metastatic burden and cachexia in murine models of cancer.

De novo and scaffold-based design of GDF15 binders for cancer cachexia diagnostics and therapeutics.

Growth differentiation factor-15 (GDF15), a stress-responsive cytokine of the transforming growth factor-β superfamily, is elevated in cancer cachexia, chemotherapy-induced nausea, and hyperemesis gravidarum, making it both a biomarker and a therapeutic target. Here, we developed high-affinity GDF15 binders using an...

🗓️ 2026-05-09
📰 Publication: Experimental And Molecular Medicine
Read MoreDe novo and scaffold-based design of GDF15 binders for cancer cachexia diagnostics and therapeutics.

Development of High-Affinity Ligands for Human UBR2.

UBR box-containing ubiquitin E3 ligases recognize the N-termini of their target proteins through the UBR box, and a member of the family, UBR2, has been established as a target to treat cancer- and diabetes-associated cachexia. However, the development of high-affinity...

🗓️ 2026-05-08
📰 Publication: Journal Of Medicinal Chemistry
Read MoreDevelopment of High-Affinity Ligands for Human UBR2.

Effectiveness and Safety of Interventions for Sarcopenia in Advanced Prostate Carcinoma: Systematic Review.

BACKGROUND

Sarcopenia has emerged as a potential prognostic factor in patients with advanced prostate cancer (PCa), requiring interventions for its prevention and treatment.

OBJECTIVE

We aimed to systematically identify, critically assess and synthesize the available evidence on the effectiveness and safety of interventions...

🗓️ 2026-05-06
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreEffectiveness and Safety of Interventions for Sarcopenia in Advanced Prostate Carcinoma: Systematic Review.

Micheliolide ameliorates colon cancer cachexia by modulating gut microbiota-immune signaling via Phocaeicola vulgatus enrichment.

BACKGROUND

Cancer cachexia profoundly impacts patient survival and quality of life. Current treatments fail to halt this trajectory, highlighting an urgent clinical need for host-directed therapies capable of uncoupling skeletal muscle wasting from tumor progression. This study investigated the therapeutic potential...

🗓️ 2026-05-06
📰 Publication: Microbiome
Read MoreMicheliolide ameliorates colon cancer cachexia by modulating gut microbiota-immune signaling via Phocaeicola vulgatus enrichment.

Sarcopenia in Patients With Cancer and Its Association With Chemotherapy-Induced Peripheral Neurotoxicity.

BACKGROUND AND OBJECTIVES

Chemotherapy-induced peripheral neurotoxicity (CIPN) is the most common neurologic complication of cancer treatment. Sarcopenia, characterized by muscle mass loss, has been associated with treatment-related toxicity, but its association with CIPN remains unclear. We aimed to assess the association...

🗓️ 2026-05-05
📰 Publication: Neurology
Read MoreSarcopenia in Patients With Cancer and Its Association With Chemotherapy-Induced Peripheral Neurotoxicity.

Biosacetalin (1,1-Diethoxyethane) Prolongs Survival and Alleviates Cachexia in the NSG Mice Bearing Neuroblastoma SH-SY5Y Cells.

Neuroblastoma remains a formidable pediatric malignancy characterized by profound metabolic plasticity and limited therapeutic responsiveness in high-risk disease. Emerging evidence positions the interplay between Reactive Oxygen Species (ROS) and the metabolic sentinel AMP-activated protein kinase (AMPK) as a critical regulator...

🗓️ 2026-05-04
Read MoreBiosacetalin (1,1-Diethoxyethane) Prolongs Survival and Alleviates Cachexia in the NSG Mice Bearing Neuroblastoma SH-SY5Y Cells.

Juyuanjian attenuates sarcopenia through dual regulation of the Akt/FoxO1 and SIRT1/PGC-1α pathways.

BACKGROUND

Sarcopenia, an age-related degenerative disease, corresponds to "Qi Xu" syndrome in traditional Chinese medicine. Juyuanjian (JYJ), a classical Qi-tonifying formula, has shown potential against muscle atrophy and functional decline, but its molecular mechanisms are not well understood.

PURPOSE

To investigate whether JYJ...

🗓️ 2026-05-03
📰 Publication: Phytomedicine
Read MoreJuyuanjian attenuates sarcopenia through dual regulation of the Akt/FoxO1 and SIRT1/PGC-1α pathways.

Cancer cachexia induces senescent reprogramming of brown adipose tissue and pro-cachectic S100A9 secretion by adipocytes.

Cancer-associated cachexia (CAC) is a multifactorial wasting syndrome characterized by progressive loss of fat and lean mass, systemic inflammation, and poor therapeutic responsiveness. While brown adipose tissue (BAT) is traditionally considered a protective, energy-dissipating organ, its qualitative remodeling in CAC...

🗓️ 2026-05-03
📰 Publication: Cell Death & Disease
Read MoreCancer cachexia induces senescent reprogramming of brown adipose tissue and pro-cachectic S100A9 secretion by adipocytes.

Elevated Circulating Ceramides 18:0 and 24:1 as a Risk Factor for Sarcopenia: In Vitro, Animal, and Clinical Evidence.

BACKGROUND

Ceramides have garnered considerable attention as pro-aging bioactive lipids implicated in both metabolic dysfunction and musculoskeletal decline. Among these, C18:0 and C24:1 ceramides may play a role in the pathophysiology of sarcopenia, a key manifestation of age-related deterioration. However, their...

🗓️ 2026-05-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreElevated Circulating Ceramides 18:0 and 24:1 as a Risk Factor for Sarcopenia: In Vitro, Animal, and Clinical Evidence.

The pathology and diagnosis of cancer cachexia and a treatment insight from natural products: A review.

Cancer cachexia, which is characterized by weight loss and muscle wasting with or without fat depletion, is a complex syndrome that commonly seen in patients with advanced cancer. The underlying pathophysiological mechanisms of cancer cachexia involve in systemic inflammation, abnormal...

🗓️ 2026-04-30
📰 Publication: Biochimica Et Biophysica Acta-Reviews On Cancer
Read MoreThe pathology and diagnosis of cancer cachexia and a treatment insight from natural products: A review.

Deubiquitinase YOD1 Inhibition Suppresses DEX- and Denervation-Induced Muscle Atrophy Through MAFbx Destabilization.

BACKGROUNDS

Muscle atrophy, characterized by progressive loss of muscle mass and function, is driven by muscle-specific E3 ligases MAFbx and MuRF1. While transcriptional regulation of E3 ligases is documented, the mechanism of their regulation by the ubiquitin-proteasome system remains unclear. This...

🗓️ 2026-04-29
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreDeubiquitinase YOD1 Inhibition Suppresses DEX- and Denervation-Induced Muscle Atrophy Through MAFbx Destabilization.

Systemic Drivers and Molecular Mechanisms of Sarcopenia in Aetiology-Specific End-Stage Liver Disease.

BACKGROUND

Patients with end-stage liver disease (ESLD) often present with sarcopenia, defined as loss of skeletal muscle mass and quality, which is associated with reduced quality of life and increased mortality. However, the molecular mechanisms driving sarcopenia in ESLD are not...

🗓️ 2026-04-27
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreSystemic Drivers and Molecular Mechanisms of Sarcopenia in Aetiology-Specific End-Stage Liver Disease.

Cancer IDO1-Mediated Tryptophan-Kynurenine Metabolic Reprogramming to Drive Skeletal Muscle Atrophy and Cachexia Acceleration.

BACKGROUND

Cancer cachexia is a debilitating syndrome characterized by severe skeletal muscle wasting, which significantly impairs patient quality of life and survival. Indoleamine 2,3-dioxygenase 1 (IDO1), a key enzyme in tryptophan (Trp) metabolism, is often upregulated in cancers, but its specific...

🗓️ 2026-04-24
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreCancer IDO1-Mediated Tryptophan-Kynurenine Metabolic Reprogramming to Drive Skeletal Muscle Atrophy and Cachexia Acceleration.

A comprehensive review of cancer-induced cardiac wasting.

Cancer is frequently accompanied by cachexia, a systemic syndrome characterized by progressive loss of skeletal muscle mass, with or without loss of fat mass. Increasing evidence indicates that cancer can also induce cardiac muscle wasting, which is associated with structural...

🗓️ 2026-04-23
📰 Publication: British Journal Of Pharmacology
Read MoreA comprehensive review of cancer-induced cardiac wasting.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!